Valuation
- Market cap
- 8,649,396,000
- Revenue TTM
- $0
- Net income TTM
- $-380,270,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 644,200
- Avg volume
- 1,102,256
- Day's range
- $92.58 – $95.82
- Shares out
- 87,350,000
- Stochastic %K
- 28%
- Beta
- 0.96
- Analysts
- Strong Sell
- Price target
- $160.15
Company profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. T...
Show more
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 33 1 53 83 09 63
- Website
- https://www.abivax.com
- Address
- 7-11 Boulevard Haussmann, Paris, France
Latest news
No headlines yet.
